Short Communication

Neurofibrillary Tangles of $\alpha\beta_{x-40}$ in Alzheimer’s Disease Brains

Ana-María Lacosta, Daniel Insua, Hassnae Badi, Pedro Pesini* and Manuel Sarasa
Araclon Biotech Ltd, Zaragoza, Spain

Accepted 20 March 2017

Abstract. The two pathognomonic lesions in the brain of AD patients are senile plaques and intraneuronal neurofibrillary tangles (NFT). Previous studies have demonstrated that amyloid-$\beta$ (A$\beta$) is a component of both senile plaques and NFTs, and have showed that intracellular accumulation of A$\beta$ is toxic for cells and precedes the appearance of extracellular amyloid deposits. Here we report that there are numerous intraneuronal NFT and extraneuronal NFT immunoreactive for A$\beta_{x-40}$ in which there is no co-localization with tau staining suggesting the existence of two different neurodegenerating populations associated with the intracellular accumulation of either tau protein or A$\beta_{x-40}$ in AD.

Keywords: Amyloid-$\beta$, $\alpha\beta$ peptides, immunohistochemistry, neurodegeneration, phosphorylated-tau, tau protein

Alzheimer’s disease (AD) is a neurodegenerative disease characterized by the progressive and irreversible destruction of neurons in the cerebral cortex. There are two pathognomonic lesions in the brain of AD patients: senile plaques, composed mainly of extracellular aggregates of amyloid-$\beta$ peptides (A$\beta$) [1], and intraneuronal neurofibrillary tangles (NFT), consisting of paired helical filaments (PHF) [2] composed primarily of hyperphosphorylated tau protein [3, 4]. The relationship between these processes is uncertain and still not completely understood. The existence of intraneuronal A$\beta$ has been known for many years. Masters and collaborators published in 1985 that A$\beta$, initially termed amyloid A4, is deposited first intraneuronally as NFT and subsequently in the extracellular space, associated with senile plaques and blood vessels [5]. Later on, the immunolabeling of most intraneuronal NFT (iNFT) and extraneuronal NFT (eNFT) with anti-A$\beta$ antibodies was replicated in several laboratories [6–8]. However, other studies failed to find A$\beta$ immunolabeling associated with iNFT [9–11] or with both iNFT and eNFT [12].

Later on, immunostaining with specific antibodies against the C-terminal fragment of either A$\beta_{40}$ or A$\beta_{42}$ (A$\beta_{x-40}$ or A$\beta_{x-42}$, respectively) enabled the visualization of A$\beta_{42}$ associated with iNFT where it was seen to colocalize with tau, whereas A$\beta_{40}$ did not associate at all or to a far lesser degree [13–15]. Additionally, it was reported that numerous eNFT appeared stained for A$\beta_{x-40}$, which was interpreted as a secondary deposition over remnants of iNFT exposed in brain tissue once the cells died; however, evidence of colocalization of A$\beta_{x-40}$ with tau protein in these eNFT was lacking [16].

Studies in cell cultures have shown that both A$\beta_{42}$ and A$\beta_{40}$ can be intracellularly produced in neurons (but apparently not in other types of cells) [17, 18], mainly in the trans-Golgi network, although production of A$\beta_{42}$ is observed as well in the endoplasmic reticulum [19]. Numerous studies have shown that the intraneuronal accumulation of A$\beta$ may be toxic and precedes its extracellular deposition both in AD brains and in transgenic mice models of the disease.
Interestingly, intraneuronal accumulation of either Aβ40 or Aβ42 has been described in brains of Down syndrome patients aged less than three years [20, 26, 27]. Furthermore, it has been found that intracellular Aβ deposition precedes the appearance of immunoreactive tau iNFT [20, 28] which subsequently were found associated with Aβ42 in neurites and synapses [15]. These findings led to a modification of the amyloid cascade hypothesis in which the first step of the cascade is the intraneuronal accumulation of Aβ [29].

In this work, we report the finding of numerous Aβx-40 positive iNFT and eNFT in the entorhinal, hippocampal and, to a lesser extent, the parietal cortex of AD brains. The Aβx-40 staining did not co-localize with tau staining in the same NFTs suggesting that there may be two different neurodegenerating pathways in AD brains leading to the intraneuronal accumulation of either tau or Aβx-40.

Paraffin embedded sections from the entorhinal, hippocampus, and parietal cortex of patients (both genders, age range 36-97) diagnosed histopathologically with AD Braak & Braak (B&B; [30]) stages II-III, IV, and VI (N = 3 from each stage), as well as from two Down syndrome (DS) patients with AD (B&B stage VI; N = 2) and from 4 healthy control brains, were immunohistochemically analyzed (for demographic characteristic, see Supplementary Table 1). The tissues were obtained from the Neurological Tissue Bank of the Clinic Hospital at the University of Barcelona in accordance with the Helsinki Declaration of 1975.

Brain sections were deparaffinized incubated for 3 minutes in 90% formic acid for antigen retrieval (except for the AT8 antibody in which a microwave was used) and quenched for endogenous peroxidase with 3.3% hydrogen peroxide and 30% methanol. The antibodies used were: SAR-022 (anti-Aβ1-40 polyclonal antibody; Araclon Biotech, Zaragoza) at 1 : 500; SAR-031 (anti-Aβ1-42 polyclonal antibody; Araclon Biotech, Zaragoza) at 1 : 2000; 6E10 monoclonal antibody (anti-N-terminal region of Aβ; Covance, London) at 1 : 2000; 4G8 monoclonal antibody (anti-central region of Aβ; Covance, London) at 1 : 1000; and AT8 (anti-Phospho-PHF-tau pSer202+Thr205; ThermoFisher Scientific, Waltham) at 1 : 200. The anti Aβx-40 and anti Aβx-42 antibodies were purified by antigen-affinity chromatography using the same Aβ fragment inoculated to the rabbits (Aβ33-40 and Aβ35-42, respectively). As described elsewhere, they have practically no cross-reactivity (less than 1%) between their target Aβ species nor with Aβ1-38 (<2%), Aβ1-43 (<1%) [31].

After overnight incubation with each primary antibody and subsequent washing, the sections were incubated for 45 min in either goat anti-rabbit at 1 : 200 (Sigma, St. Louis) or goat anti-mouse at 1 : 100 (Sigma, St. Louis) for poly- or monoclonal primary antibodies, respectively; followed by 45 min incubation in avidin-biotin (Vectastain ABC kit, Vector lab, Burlingame) and then developed with diaminobenzidine as chromogen. Selected sections were double immunofluorescence stained with anti-Aβx-40 and AT8 antibodies followed by rodamine-goat anti-rabbit at 1 : 100 (Sigma, St. Louis) or fluorescein-goat anti-mouse at 1 : 100 (Sigma, St. Louis). Specificity of the anti-Aβx-40 labeling was assessed by overnight preadsorption of the primary antibody with Aβ1-40 peptide (10e-5 M).

The section labeled with the anti-Aβx-40 antibody presented (in addition to positively stained diffuse and senile plaques) numerous Aβx-40 positive NFTs. These Aβ-NFTs were intensely stained and appeared very similar to the classic tau-NFTs. The Aβ-NFTs were localized in the entorhinal cortex, mainly in the cell islands of layer II, but also in deeper cortical layers (Fig. 1A); in the hippocampus, including dentate gyrus, fields CA1-CA3, and in the subiculum (Fig. 1B) of all the patients analyzed (Braak & Braak stages II-III, IV, and VI) and, to a lesser extent, dispersed within the parietal cortex of the more advanced cases of AD. No Aβ-NFTs were observed in the preparations from the healthy control brains.

Aβx-40 positive labeling was seen in the cytoplasm of apparently functional neurons as iNFTs (Fig. 1C, D), but labeling of eNFT was more frequently seen, particularly in advanced AD stages (Fig. 1D). Many of these eNFTs maintained the shape of neurons, although they were normally larger than their unlabeled counterparts, which suggested that these profiles could represent an additional Aβx-40 deposition once the parental neurons have lost their plasmatic membrane, leaving the NFTs exposed in the neuropil.

In contrast to the intense labelling obtained with the anti-Aβx-40 antibody, we did not see NFT labelling with any of the anti-Aβ monoclonal antibodies that target the N-terminal or central parts of the Aβ peptides, which indicated that Aβ-NFTs were composed of Aβ C-terminal fragments (Fig. 1E, F). Very occasionally we found similar iNFTs and eNFTs marked with the anti-Aβ42 antibody (not shown).
**Fig. 1.** A-F) Aβ<sub>40</sub> immunostaining of AD brain sections (B&B stage VI). A) Clusters of Aβ<sub>40</sub> positive NFT are seen in layer II and scattered in deeper layers of entorhinal cortex together with slightly stained senile plaques (arrow heads). B) In the hippocampal formation, Aβ<sub>40</sub> positive NFT appeared mainly in the CA1-CA3 fields and in the dentate gyrus. C) Aβ<sub>40</sub> positive iNFT in the hippocampus (arrow heads). D) Aβ<sub>40</sub> eNFT and iNFT (arrow heads) in the entorhinal cortex. E, F) The sections reacted with 6E10 (E) or 4G8 (F) showing numerous senile plaques but no NFT; asterisks are in the same blood vessel for reference.

Aβ-NFTs were also found in the brain of a DS patient who had been diagnosed with severe dementia of Alzheimer type. Interestingly, these Aβ<sub>40</sub> positive profiles were almost completely lacking in the other non-demented DS patient, in spite of both having been classified as B&B stage VI and both presented extensive Aβ<sub>42</sub> burden (Fig. 2A-D).

The preadsorption of the anti-Aβ<sub>40</sub> antibody with Aβ<sub>1-40</sub> led to the complete disappearance of staining in both the senile plaques and Aβ-NFTs, demonstrating that the labeling is due to the presence of the Aβ<sub>40</sub> C-terminal fragments specifically recognized by our Aβ<sub>40</sub> antibody (Fig. 2E, F). Furthermore, double immunofluorescent staining showed that the epitopes for the anti-Aβ<sub>40</sub> and AT8 antibodies do not colocalize on the same neurons, whereas they positively colocalize on the diffuse and senile plaques (Fig. 3A-F). These findings allowed us to discard the possibility of that the labelling of Aβ-NFTs was due to a cross-reactivity of our antibody with the tau-NFTs. Thus, two populations of degenerating neurons could be detected and differentiated, one filled with tau and the other with C-terminal fragments of Aβ<sub>40</sub>.
An exaggeratedly antagonistic vision of the two hallmark lesions in AD (extracellular senile plaques mainly containing Aβ and intraneuronal NFTs composed of hyperphosphorylated tau protein) has crystallized into the idea that Aβ triggers neurodegeneration from the outside of cells and a subsequent tau accumulation damages them from inside. This overly simplistic vision disregards pioneers’ results demonstrating that Aβ is a component of both senile plaques and NFTs [5, 8, 9, 32] and also more recent reports showing that intracellular accumulation of Aβ is toxic for cells and precedes the appearance of extracellular amyloid deposits [14, 20, 22–27, 29]. The presence of Aβ_{40} immunoreactivity in the eNFTs as described in the present work, has been known for a long time [13, 16], yet contradictory results have also been reported [14, 20]. These discrepancies suggest that not all anti-Aβ_{40} specific antibodies are able to recognize the Aβ_{40} C-terminal fragments present in the NFT, although they could also be due to differences in the processing of brain sections [8, 33, 34].
Since the majority of the eNFTs found in those studies were Aβ40 positive, whereas, in contrast, very few iNFTs appeared labelled with anti-Aβ40 antibodies, it was assumed that eNFTs resulted from a secondary deposition of extracellular Aβ40 once the neuron had died and lost its nucleus and its plasmatic membrane. Visualization of tau positive eNFTs was not present in these studies because they were predominantly carried out with the Alz-50 antibody, which targets a tau-epitope known to be lost in the eNFTs [10, 32]. However, in the present work we have used the monoclonal AT8 anti-tau antibody, which has allowed us to label both tau positive iNFT and eNFT, in accordance with previous reports [35]. Interestingly, the Aβx-40 staining does not co-localize with the tau staining in the same NFT, while it does co-localize in the diffuse and senile plaques. Thus, two populations of degenerating neurons can be differentiated in a brain with AD, suggesting the existence of at least two different neurodegenerating pathways leading to the intraneuronal accumulation of either tau or Aβx-40.

Nevertheless, further experiments analyzing more brains, a larger panel of antibodies targeting not only Aβ40 and phosphorylated tau but also native tau, the ultrastructural characterization of Aβx-40 NFTs and their timeline throughout the disease process, will be necessary to test this hypothesis.

In spite of its limitations, the present work comments on the role of Aβ40 in AD which is also underlined by our finding of numerous Aβx-40 positive profiles in the brain of a Down syndrome patient with severe dementia while these profiles were almost completely lacking in the brain of a non-demented Down syndrome patient. Although there are controversial reports concerning which Aβ species accumulates intracellularly in DS patients, our result is congruent with previous studies showing an increase of Aβ40 immunoreactive profiles in the brains of Down syndrome patients from 30 years old onwards, when neuropathology rapidly accumulates until it reaches levels sufficient for a diagnosis of AD in most of these patients (for a recent review, see [36]). Currently, it is generally accepted that Aβ42 may be of particular relevance in triggering AD because it is more hydrophobic and prone to aggregate \textit{in vitro} than Aβ40 [37]. However, it should be considered that the aggregating behavior of the various Aβ species could be different \textit{in vivo} than \textit{in vitro} [38] and, in this line, it is also relevant to underline some studies pointing to the relevance of Aβ40 in AD [39, 40].

In conclusion, the present work underlines the possible role for Aβ40 in AD physiopathology as our results have shown the existence of two different neurodegenerating populations alternatively...
associated with the intracellular accumulation of either tau protein or Aβx-40.

ACKNOWLEDGMENTS

This work has been financed by Araclon Biotech Ltd.

Authors’ disclosures available online (http://j-alz.com/manuscript-disclosures/17-0163r1).

SUPPLEMENTARY MATERIAL

The supplementary material is available in the electronic version of this article: http://dx.doi.org/10.3233/JAD-170163.

REFERENCES


